002317 众生药业
已收盘 05-29 15:00:00
资讯
新帖
简况
众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》
证券之星 · 05-28 20:51
众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》
华鑫证券:给予众生药业买入评级
证券之星 · 05-28
华鑫证券:给予众生药业买入评级
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
证券之星 · 05-27
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-27
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐
证券之星 · 05-26
众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐
众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%
证券之星 · 05-25
众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%
【机构调研记录】惠升基金调研众生药业
证券之星 · 05-21
【机构调研记录】惠升基金调研众生药业
股市必读:众生药业(002317)5月20日董秘有最新回复
证券之星 · 05-21
股市必读:众生药业(002317)5月20日董秘有最新回复
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
证券之星 · 05-20
众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药
【机构调研记录】摩根士丹利基金调研众生药业、东威科技
证券之星 · 05-18
【机构调研记录】摩根士丹利基金调研众生药业、东威科技
众生药业:ZSP1601片是治疗MASH首创一类创新药
证券之星 · 05-14
众生药业:ZSP1601片是治疗MASH首创一类创新药
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
证券之星 · 05-14
众生药业:公司正在积极推进RAY1225注射液的III期临床试验
众生药业最新公告:昂拉地韦颗粒新药上市申请获得受理
证券之星 · 05-13
众生药业最新公告:昂拉地韦颗粒新药上市申请获得受理
东海证券:给予众生药业买入评级
证券之星 · 05-12
东海证券:给予众生药业买入评级
众生药业最新公告:全资子公司获盐酸氨酮戊酸原料药上市批准
证券之星 · 05-11
众生药业最新公告:全资子公司获盐酸氨酮戊酸原料药上市批准
众生药业涨10.00%,开源证券一周前给出“买入”评级
证券之星 · 05-08
众生药业涨10.00%,开源证券一周前给出“买入”评级
众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%
证券之星 · 05-07
众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%
众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极
证券之星 · 05-07
众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极
今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动
证券之星 · 05-07
今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动
股市必读:众生药业(002317)5月6日董秘有最新回复
证券之星 · 05-07
股市必读:众生药业(002317)5月6日董秘有最新回复
加载更多
公司概况
公司名称:
广东众生药业股份有限公司
所属行业:
医药制造业
上市日期:
2009-12-11
主营业务:
广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。
发行价格:
55.00
{"stockData":{"symbol":"002317","market":"SZ","secType":"STK","nameCN":"众生药业","latestPrice":23.54,"timestamp":1780038192000,"preClose":22.6,"halted":0,"volume":52209189,"delay":0,"changeRate":0.0416,"floatShares":762000000,"shares":850000000,"eps":0.3447,"marketStatus":"已收盘","change":0.94,"latestTime":"05-29 15:00:00","open":22.8,"high":23.96,"low":22.5,"amount":1220000000,"amplitude":0.0646,"askPrice":23.54,"askSize":3,"bidPrice":23.53,"bidSize":32,"shortable":0,"etf":0,"ttmEps":0.3447,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":22.6,"symbolType":"stock","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":24.86,"lowLimit":20.34,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":849930477,"isCdr":false,"pbRate":4.66,"roa":"--","peRate":68.291268,"roe":"2.43%","epsLYR":0.33,"committee":0.551134,"marketValue":20007000000,"turnoverRate":0.0686,"status":0,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-06-01。","floatMarketCap":17928000000},"requestUrl":"/m/hq/s/002317/","defaultTab":"news","newsList":[{"id":"2638695161","title":"众生药业:ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695161","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638695161?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:51","pubTimestamp":1779972703,"startTime":"0","endTime":"0","summary":"投资者提问:ZSP1601的二期实验数据有没有发表在顶级刊物上?公司ZSP1601片是具有全球自主知识产权、全新作用机制的治疗代谢功能障碍相关脂肪性肝炎首创一类创新药,目前已获得IIb期临床试验的顶线分析数据。ZSP1601片Ib/IIa期临床试验结果已发表在自然杂志子刊《Nature Communications》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800041163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515416","title":"华鑫证券:给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515416","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638515416?lang=zh_cn&edition=full","pubTime":"2026-05-28 12:03","pubTimestamp":1779940998,"startTime":"0","endTime":"0","summary":"华鑫证券有限责任公司胡博新近期对众生药业进行研究并发布了研究报告《公司事件点评报告:稳步推进新药研发》,给予众生药业买入评级。 昂拉地韦持续累积优效临床证据 昂拉地韦为全球首款流感RNA聚合酶PB2蛋白抑制剂,靶点差异于奥司他韦和玛巴洛沙韦。最新盈利预测明细如下:该股最近90天内共有5家机构给出评级,买入评级5家;过去90天内机构目标均价为21.66。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800018882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574047","title":"众生药业:公司正在积极推进RAY1225注射液的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574047?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:04","pubTimestamp":1779865457,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的减肥药,糖尿病药物RAY1225三期试验什么时候结束?公司会参加2026年6月初美国糖尿病大会吗?众生药业回复:您好!公司正在积极推进RAY1225注射液的III期临床试验,有关创新药的进展情况请以公司公告为准。公司始终关注行业交流机会,积极参与美国糖尿病协会科学年会会议,并将围绕创新成果与合作机遇展开深度交流与分享,助力公司完善国际化布局,加速创新成果的转化与共享。谢谢!以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","002317","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638574447","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2638574447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638574447?lang=zh_cn&edition=full","pubTime":"2026-05-27 15:00","pubTimestamp":1779865244,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月26日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年5月底了,怎么还看不到昂拉地韦25年流感季的销量?是否在做数据?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700024434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1161","002317","06978","BK0239","BK0188","BK0077","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638596451","title":"众生药业:公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐","url":"https://stock-news.laohu8.com/highlight/detail?id=2638596451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638596451?lang=zh_cn&edition=full","pubTime":"2026-05-26 15:00","pubTimestamp":1779778853,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月25日在投资者关系平台上答复投资者关心的问题。投资者提问:Zsp1601数据非常牛,公司怎么拓展海外市场?众生药业回复:您好!公司始终重视药品的国外市场机会以及药品海外市场广阔机遇与增长空间。公司立足自身产品优势与研发实力,坚持稳健布局、审慎推进的原则,适时拓展海外市场,加快国际化推进步伐。谢谢!以上内容为证券之星据公开信息整理,不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052600020027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638531550","title":"众生药业(002317)披露2025年年度权益分派实施公告,5月25日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638531550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638531550?lang=zh_cn&edition=full","pubTime":"2026-05-25 17:36","pubTimestamp":1779701780,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,众生药业报收于23.7元,较前一交易日下跌0.88%,最新总市值为201.43亿元。该股当日开盘23.75元,最高24.35元,最低23.1元,成交额达10.63亿元,换手率为5.9%。近日,众生药业发布《2025年年度权益分派实施公告》。公告显示,公司2025年年度权益分派方案为:以公司总股本849,930,477股为基数,向全体股东每10股派发现金红利2.00元(含税),不送红股,不以公积金转增股本,共计派发现金红利169,986,095.40元。本次分配方案与股东会审议通过的一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500024799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","002317","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637874681","title":"【机构调研记录】惠升基金调研众生药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2637874681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637874681?lang=zh_cn&edition=full","pubTime":"2026-05-21 08:01","pubTimestamp":1779321706,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月20日披露的机构调研信息,惠升基金近期对1家上市公司进行了调研,相关名单如下:1)众生药业 个股亮点:公司深度融合互联网技术与创新商业模式,打造精准化医疗解决方案,面向医务工作者提供智能化诊疗支持。旗下最近一年表现最佳的公募基金产品为惠升惠远回报混合A,最新单位净值为1.29,近一年增长63.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100007554.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","002317","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637245858","title":"股市必读:众生药业(002317)5月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637245858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637245858?lang=zh_cn&edition=full","pubTime":"2026-05-21 01:08","pubTimestamp":1779296891,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,众生药业报收于24.52元,上涨3.94%,换手率9.68%,成交量73.7万手,成交额18.05亿元。来自公司公告汇总:众生药业2025年度股东会于2026年5月20日召开,审议通过利润分配预案、续聘审计机构、为子公司提供担保额度及董事高管薪酬相关议案,会议被认定为合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002317","BK0239","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847667","title":"众生药业:昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847667","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636847667?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:53","pubTimestamp":1779281599,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月20日在投资者关系平台上答复投资者关心的问题。投资者提问:已经26年5月了,怎么看不到贵公司昂拉地韦片25年销量?股民有权知道25年每月销量吗?26年1季度销量能公布吗?众生药业回复:您好!昂拉地韦片是全球首款靶向甲型流感病毒RNA聚合酶PB2亚基的一类创新药,适用于成人单纯性甲型流感患者的治疗,销售与流感季节性相关。公司正持续推进学术推广与渠道建设,后续将结合流感周期与医保落地效应,稳步推动昂拉地韦片的商业化工作。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002317","BK1574","159992","BK0077","BK1161","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012980","title":"【机构调研记录】摩根士丹利基金调研众生药业、东威科技","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636012980?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:02","pubTimestamp":1779062541,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息及5月15日披露的机构调研信息,摩根士丹利基金近期对2家上市公司进行了调研,相关名单如下:1)众生药业 调研纪要:ZSP1601片IIb期临床试验结果显示,两个剂量组主要疗效终点应率分别为64.9%和57.6%,显著优于安慰剂组的32.5%,且在纤维化改善、肝脏脂肪含量下降及肝酶指标方面均显著改善。安全性良好,不良事件发生率与安慰剂组相当。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800002707.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","688700","BK0251","002317","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750938","title":"众生药业:ZSP1601片是治疗MASH首创一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750938","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635750938?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:48","pubTimestamp":1778719692,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业05月13日在投资者关系平台上答复投资者关心的问题。请问公司1601非酒精型脂肪肝创新药对酒精性脂肪肝是否具有治疗效果?公司ZSP1601片是具有全球自主知识产权、全新作用机制的治疗代谢功能障碍相关脂肪性肝炎首创一类创新药,为国家重大新药创制项目。公司始终以满足未被满足的临床需求为导向,未来,公司将根据实际情况,综合考虑ZSP1601片的适应症拓展,相关信息请以公司公告为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002317","159992","06978","BK0077","BK1161","BK1574","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635509607","title":"众生药业:公司正在积极推进RAY1225注射液的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2635509607","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635509607?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:45","pubTimestamp":1778719511,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业(002317)05月13日在投资者关系平台上答复投资者关心的问题。投资者提问:公司的RAY1225创新三期试验进展如何?减重版三期试验什么时间全部结束?读取数据大概需要多长时间?众生药业回复:您好!公司正在积极推进RAY1225注射液的III期临床试验,有关创新药的进展情况请以公司公告为准。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0188","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635895047","title":"众生药业最新公告:昂拉地韦颗粒新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2635895047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635895047?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:11","pubTimestamp":1778670669,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司控股子公司众生睿创研发的昂拉地韦颗粒(用于治疗2~11岁儿童单纯性甲型流感)新药上市申请已获国家药监局受理。该药品为儿童及吞咽困难患者设计,III期临床试验显示积极疗效和良好安全性。但新药上市申请尚需审评、审批,存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300038107.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","002317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634294107","title":"东海证券:给予众生药业买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634294107","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634294107?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:29","pubTimestamp":1778578158,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,付婷近期对众生药业进行研究并发布了研究报告《公司简评报告:主业稳健增长,创新成果逐步兑现》,给予众生药业买入评级。RAY1225注射液减重及降糖适应症国内授权给齐鲁制药,未来商业化可期,同时积极探索海外市场。公司主营业务稳健,创新管线快速推进,维持“买入”评级。最新盈利预测明细如下:该股最近90天内共有3家机构给出评级,买入评级3家;过去90天内机构目标均价为21.66。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200029852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634026554","title":"众生药业最新公告:全资子公司获盐酸氨酮戊酸原料药上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2634026554","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634026554?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:40","pubTimestamp":1778492448,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司全资子公司广东先强药业近日收到国家药监局核准签发的盐酸氨酮戊酸《化学原料药上市申请批准通知书》。该原料药可用于治疗尖锐湿疣,2023年至2025年相关制剂在中国城市公立医院及实体药店年销售额分别为3.56亿元、4.06亿元、4.45亿元。此次获批将丰富公司特色原料药产品管线,但不会对当期业绩产生重大影响,销售情况存在不确定性。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100024858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633353434","title":"众生药业涨10.00%,开源证券一周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633353434","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633353434?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:28","pubTimestamp":1778228899,"startTime":"0","endTime":"0","summary":"今日众生药业(002317)涨10.00%,收盘报22.54元。2026年4月30日,开源证券研究员余汝意,巢舒然发布了对众生药业的研报《公司信息更新报告:2025年经营业绩稳健提升,创新布局赋能发展》,该研报对众生药业给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为79.6%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为信达证券的唐爱金、贺鑫。众生药业(002317)个股概况:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800028652.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633207123","title":"众生药业(002317)披露控股子公司ZSP1601片IIb期临床试验初步结果,5月7日股价上涨9.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633207123","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633207123?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:03","pubTimestamp":1778162597,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,众生药业报收于20.49元,较前一交易日上涨9.98%,最新总市值为174.15亿元。近日,众生药业披露关于控股子公司治疗MASH一类创新药ZSP1601片IIb期临床试验初步结果的公告。公告显示,广东众生药业控股子公司众生睿创自主研发的一类创新药ZSP1601片,在治疗代谢功能障碍相关脂肪性肝炎的IIb期临床试验中取得积极顶线数据。公司将推进与监管部门沟通,计划开展III期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002317","BK0077","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633418961","title":"众生药业最新公告:MASH创新药ZSP1601片IIb期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2633418961","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633418961?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:39","pubTimestamp":1778153999,"startTime":"0","endTime":"0","summary":"众生药业(002317.SZ)公告称,公司控股子公司众生睿创自主研发的MASH一类创新药ZSP1601片IIb期临床试验顶线数据初步分析结果积极。两个剂量组主要疗效终点应答率均显著优于安慰剂组,100mg组、50mg组和安慰剂组应答率分别为64.9%、57.6%和32.5%。ZSP1601片具有逆转肝纤维化潜力,可快速降低肝脏脂肪含量并改善肝酶指标,安全性和耐受性良好。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700036269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","06978","BK1574","BK0239","002317","BK1161","BK0077","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138971","title":"今日众生药业(002317)涨停分析:创新药商业化+业绩增长+财务优化驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138971","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633138971?lang=zh_cn&edition=full","pubTime":"2026-05-07 15:42","pubTimestamp":1778139767,"startTime":"0","endTime":"0","summary":"证券之星消息,众生药业5月7日涨停收盘,收盘价20.49元。今日众生药业涨停的可能因素有:创新药商业化加速,两款一类新药获批上市并纳入医保,昂拉地韦儿童适应症临床积极,RAY1225完成III期入组并获2亿元商业化首付款;2025年成功扭亏为盈,归母净利润2.76亿元、同比增超190%,2026年一季度业绩持续增长;财务结构显著优化,大额有息负债清偿完毕,资产负债率下降,前期冻结资产全部解冻,流动性压力缓解;公司治理合规达标,增强市场信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700020448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","BK0077","BK0239","002317","BK0188","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633153489","title":"股市必读:众生药业(002317)5月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633153489","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633153489?lang=zh_cn&edition=full","pubTime":"2026-05-07 02:00","pubTimestamp":1778090450,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,众生药业报收于18.63元,上涨1.31%,换手率3.25%,成交量24.78万手,成交额4.61亿元。董秘最新回复投资者: 尊敬的董秘,贵公司一季报出来后,作为1名投资者深感失望,昂拉地韦作为国家1类创新药,贵公司的推广进度实在差强人意,对比青峰药业的流感药,差距明显。投资者: 请问2025年4季度和2026年1季度昂拉地韦的销量和销售收入分别是多小董秘: 您好!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700001344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","BK0188","002317"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780210119275,"stockEarnings":[{"period":"1week","weight":-0.0068},{"period":"1month","weight":0.2892},{"period":"3month","weight":0.2512},{"period":"6month","weight":-0.0085},{"period":"1year","weight":0.7449},{"period":"ytd","weight":0.2512}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东众生药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"111004人(较上一季度减少2.61%)","perCapita":"6861股","listingDate":"2009-12-11","address":"广东省东莞市石龙镇西湖工业区信息产业园","registeredCapital":"84993万元","survey":" 广东众生药业股份有限公司的主营业务是药品研发、生产和销售。公司的主要产品是昂拉地韦片、来瑞特韦片、复方血栓通系列产品、脑栓通胶囊、复方丹参片、众生丸系列产品、清热祛湿颗粒、羧甲司坦口服溶液(片)、盐酸氨溴索口服溶液、头孢克肟分散片、头孢拉定胶囊、异烟肼片、吡嗪酰胺片、盐酸乙胺丁醇片、利福平胶囊、利巴韦林片、硫糖铝口服混悬液、瑞巴派特片、奥美拉唑肠溶胶囊、盐酸氮䓬斯汀滴眼液、普拉洛芬滴眼液、地夸磷索钠滴眼液、环孢素滴眼液(III)、氯雷他定片、富马酸氯马斯汀口服溶液。","listedPrice":55},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"众生药业,002317,众生药业股票,众生药业股票老虎,众生药业股票老虎国际,众生药业行情,众生药业股票行情,众生药业股价,众生药业股市,众生药业股票价格,众生药业股票交易,众生药业股票购买,众生药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"众生药业(002317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供众生药业(002317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}